11:46 AM EDT, 04/03/2024 (MT Newswires) -- Neurocrine Biosciences ( NBIX ) said Wednesday that it has dosed the first patient for its phase 2 clinical study of a potential treatment for major depressive disorder in adults.

The study will assess the efficacy and safety of investigational compound NBI-1070770 in people who have major depressive disorder compared with placebo on easing symptoms of depression, the company said.

The study will enroll about 72 adults and is being held at centers in the US, Neurocrine said.

Price: 137.40, Change: -0.34, Percent Change: -0.25